Pfizer has set its financial sights for 2025, projecting total revenues in the range of $61.0 billion to $64.0 billion. This forecast anticipates operational revenue growth from flat to 5% compared to the midpoint of 2024 guidance, excluding $1.2 billion of non-recurring revenues for Paxlovid. Adjusted earnings are expected to be between $2.80 and $3.00, indicating a year-over-year operational growth of 10%-18% from the 2024 midpoint, excluding certain non-recurring items.
In the realm of medical advancements, Sanofi and Teva Pharmaceutical have reported that their phase IIb study on duvakitug (TEV’574), a candidate for treating ulcerative colitis and Crohn’s disease, has successfully met its primary endpoints. The study showed promising results, with a significant percentage of patients achieving clinical remission and endoscopic response compared to placebo. This success paves the way for a phase III program, with Sanofi leading the clinical development.
Merck has made a strategic move into the obesity market by securing an exclusive global licensing deal with China’s Hansoh Pharma for a preclinical GLP-1 receptor agonist, HS-10535. The agreement includes an upfront payment of $112 million to Hansoh Pharma, with potential milestone payments and royalties totaling up to $1.9 billion. Hansoh retains the option to co-promote or solely commercialize HS-10535 in China, marking a significant entry for Merck into a highly lucrative market segment.
